France's Abivax Looks A Likely M&A Target

ABX464 Could Be IBD Gamechanger

With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.

Spotlight
Abivax in the spotlight • Source: Alamy

No acquisitions were announced at J.P. Morgan this week but Abivax SA could soon find itself the subject of some serious takeover speculation following the French biotech's upbeat presentation at the high-profile healthcare conference centred around its Phase III-ready candidate, ABX464, for chronic inflammatory diseases.

The presentation came hours after EU regulators, just like the US Food and Drug Administration a month earlier, supported the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business